HUTCHMED (China) Limited (NASDAQ:HCM – Get Free Report)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $14.18, but opened at $13.70. HUTCHMED shares last traded at $13.37, with a volume of 40,432 shares changing hands.
Wall Street Analyst Weigh In
Separately, StockNews.com lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Monday, November 18th.
Read Our Latest Stock Analysis on HUTCHMED
HUTCHMED Trading Down 0.3 %
Hedge Funds Weigh In On HUTCHMED
Large investors have recently bought and sold shares of the stock. Jane Street Group LLC increased its holdings in shares of HUTCHMED by 362.2% during the 3rd quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock worth $1,305,000 after purchasing an additional 49,366 shares during the period. State Street Corp grew its position in HUTCHMED by 0.9% during the third quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after buying an additional 3,078 shares in the last quarter. Rhumbline Advisers increased its stake in HUTCHMED by 8.1% during the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after acquiring an additional 564 shares during the period. M&G PLC raised its holdings in HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company’s stock valued at $5,345,000 after acquiring an additional 132,333 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after acquiring an additional 3,057 shares during the period. 8.82% of the stock is currently owned by institutional investors and hedge funds.
HUTCHMED Company Profile
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
See Also
- Five stocks we like better than HUTCHMED
- Pros And Cons Of Monthly Dividend Stocks
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
- Most Volatile Stocks, What Investors Need to Know
- MarketBeat Week in Review – 01/20 – 01/24
- Why Are These Companies Considered Blue Chips?
- Netflix Stock Positioned for Explosive Growth in 2025
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.